DealShare, once valued at $1.7 billion, is in advanced talks to be acquired by online pharmacy platform Truemeds in a share-swap transaction that could value the struggling e-commerce company at only a little above its $90 million cash balance. The proposed deal would represent a dramatic reset for a startup that became a unicorn in 2022 after raising substantial venture capital from global investors.
Under the reported structure, Truemeds would issue shares to DealShare’s investors at a valuation of approximately $600 million, while DealShare itself would be valued at its cash on books plus a small premium. The transaction would allow Truemeds to acquire DealShare without paying cash upfront, while DealShare’s shareholders would receive equity in the online pharmacy. The final terms are still being negotiated and the deal has not been formally announced.
DealShare’s $1.7 Billion Valuation Could Collapse
DealShare’s potential sale illustrates one of the sharpest valuation corrections among India’s consumer internet startups.
The company reached a valuation of about $1.7 billion in 2022, after raising a $210 million funding round. It had raised approximately $393 million from investors over its lifetime.
The proposed transaction could value the operating company at only slightly above its cash balance of roughly $90 million.
DealShare Valuation Journey
| Stage | Reported Valuation |
|---|---|
| 2022 peak | ~$1.7 billion |
| Cash balance | >$90 million |
| Proposed DealShare valuation | Slightly above $90 million |
| Proposed Truemeds valuation | ~$600 million |
| Potential valuation decline from peak | ~95%+ |
The proposed valuation represents a dramatic decline from the price investors were willing to pay during the funding boom.
If DealShare were valued at exactly $90 million, the decline from $1.7 billion would be approximately 94.7%. Because the proposed value is described as slightly above the cash balance, the actual decline would be somewhat lower.
What The Proposed Truemeds Deal Looks Like
The transaction is structured differently from a conventional acquisition.
Instead of Truemeds paying DealShare’s shareholders a large cash consideration, the online pharmacy would issue new shares.
DealShare investors would therefore exchange their interest in the struggling e-commerce company for ownership in Truemeds.
Proposed Deal Structure
DealShare investors
│
▼
Give up DealShare ownership
│
▼
Receive Truemeds shares
│
▼
Truemeds valuation
~$600 million
│
▼
Truemeds acquires DealShare
│
▼
DealShare cash + selected assets/network
The structure would also allow Truemeds to gain access to DealShare’s cash without making a large upfront cash payment.
DealShare’s Revenue Has Collapsed
The valuation reset is closely connected to the company’s declining revenue.
DealShare’s revenue from operations fell from ₹1,963 crore in FY23 to ₹499 crore in FY24, before declining further to ₹432 crore in FY25.
That represents a dramatic contraction from the company’s earlier scale.
DealShare Revenue Trend
| Financial Year | Revenue From Operations |
|---|---|
| FY23 | ₹1,963 crore |
| FY24 | ₹499 crore |
| FY25 | ₹432 crore |
| FY23-FY25 decline | ~78% |
The fall in revenue indicates that DealShare’s efforts to scale back operations and reduce costs have come at the expense of its top line.
Losses Have Narrowed, But Revenue Keeps Falling
DealShare’s financial performance does contain one positive element: losses have declined.
The company’s net loss narrowed to approximately ₹87.65 crore in FY25, compared with ₹167 crore in FY24.
However, the improvement came alongside another decline in revenue.
DealShare Financial Performance
| Metric | FY24 | FY25 | Change |
|---|---|---|---|
| Revenue | ₹499 crore | ₹432 crore | -13.4% |
| Net loss | ₹167 crore | ₹87.65 crore | ~47.5% lower |
| Revenue direction | ↓ | ↓ | Continued contraction |
This suggests that cost-cutting helped reduce losses, but the company has not yet demonstrated a return to sustainable growth.
DealShare Has Been Shrinking Its Operations
DealShare’s business has contracted significantly after years of challenges.
The company previously operated a social-commerce model focused on group buying and low-priced groceries and household products, particularly for consumers in smaller cities.
As the business struggled, it reduced operations, cut staff and eventually shut down its business-to-business vertical.
DealShare’s Retrenchment
| Development | Impact |
|---|---|
| Revenue decline | Smaller business scale |
| Employee layoffs | Lower operating costs |
| B2B vertical shutdown | Narrower business |
| Management changes | Leadership transition |
| Cost cuts | Lower losses |
| Reduced operations | Weaker growth potential |
The company’s latest financial trajectory suggests that cost reduction alone was not enough to restore the earlier growth model.
From Unicorn To Distressed Sale
DealShare became a unicorn in January 2022, joining India’s rapidly expanding group of startups valued at more than $1 billion.
The company’s valuation subsequently reached about $1.7 billion after another funding round.
The contrast with the proposed 2026 transaction is stark.
2022
│
▼
$1.7B valuation
│
▼
Aggressive expansion
│
▼
Revenue contraction
│
▼
Cost cutting
│
▼
Business vertical shutdown
│
▼
2026
│
▼
Potential sale near cash value
The journey reflects the broader reset in India’s startup market following the end of the easy-money era.
DealShare Raised About $393 Million
The company attracted substantial institutional backing during its growth phase.
DealShare raised about $393 million from investors including Tiger Global, ADIA, Alpha Wave Global and Kora Investment, according to industry reports.
Its funding history shows how dramatically investor expectations have changed.
Major DealShare Funding Context
| Indicator | Reported Figure |
|---|---|
| Total capital raised | ~$393 million |
| 2022 funding round | $210 million |
| Peak valuation | ~$1.7 billion |
| Current cash balance | >$90 million |
| Proposed sale value | Slightly above cash balance |
The potential transaction would therefore represent a major impairment for investors who participated at substantially higher valuations.
WestBridge Capital Links Truemeds And DealShare
The proposed transaction has another notable feature: WestBridge Capital is an investor in both companies.
That shared investor relationship could help facilitate the transaction.
DealShare investors would receive shares in Truemeds rather than cash, creating a new ownership structure in which existing DealShare backers become shareholders of the combined business.
Common Investor Connection
WestBridge Capital
/ \
/ \
▼ ▼
DealShare Truemeds
\ /
\ /
▼ ▼
Proposed
share swap
A common investor does not guarantee that the transaction will close, but it can simplify discussions around valuation and shareholder interests.
Why Truemeds Is Interested In DealShare
Truemeds operates in online pharmacy and telehealth, a very different market from DealShare’s original grocery-focused business.
The strategic rationale therefore appears to be less about acquiring DealShare’s consumer brand and more about gaining access to its cash and distribution infrastructure.
DealShare’s network outside major metropolitan areas could complement Truemeds’ efforts to expand fulfillment capacity beyond large cities.
Potential Benefits For Truemeds
| DealShare Asset | Potential Truemeds Benefit |
|---|---|
| Cash balance | Adds financial resources |
| Non-metro network | Supports smaller-city expansion |
| Distribution capabilities | Potential fulfillment advantages |
| Supply-chain experience | Operational knowledge |
| Existing infrastructure | Potentially reduces expansion time |
| DealShare investors | New shareholder base |
The proposed transaction would therefore be different from a conventional acquisition aimed at acquiring a fast-growing consumer business.
Truemeds Has Been Expanding
The proposed DealShare transaction comes after Truemeds raised $85 million in a funding round led by Accel and Peak XV Partners.
The company has been investing in fulfillment capacity and expanding its presence beyond India’s largest metropolitan areas.
Truemeds reported ₹510 crore in net revenue for FY25, compared with ₹315 crore in the previous year, according to Venture Intelligence.
Truemeds Financial Snapshot
| Metric | FY24 | FY25 |
|---|---|---|
| Net revenue | ₹315 crore | ₹510 crore |
| Revenue growth | — | ~61.9% |
| Recent funding | — | $85 million |
| Proposed valuation in DealShare transaction | — | ~$600 million |
The contrast with DealShare’s shrinking revenue is significant.
DealShare’s Smaller-City Network Could Be Useful
DealShare originally built its business around serving consumers in smaller cities and towns.
That focus created a sourcing and distribution network outside India’s largest urban markets.
Truemeds is also seeking to expand its fulfillment capabilities nationally, making DealShare’s infrastructure potentially useful for the pharmacy platform.
Geographic Strategy
| Company | Historical / Current Focus |
|---|---|
| DealShare | Smaller cities, affordable groceries |
| Truemeds | Online pharmacy and telehealth |
| Potential overlap | Non-metro distribution |
| Potential combined benefit | Wider fulfillment reach |
Whether the network remains economically useful will depend on how much of DealShare’s infrastructure is still operational.
DealShare’s Business Model Lost Momentum
DealShare initially benefited from strong investor interest in social commerce and low-cost e-commerce.
Its group-buying model was designed to combine customers and reduce product costs.
But the competitive environment became significantly more difficult as India’s online commerce market matured.
Larger platforms expanded their reach, quick-commerce companies changed consumer expectations and investors became more focused on profitability.
E-Commerce Market Shift
Early startup phase
│
▼
Growth + user acquisition
│
▼
High private valuations
│
▼
Market competition intensifies
│
▼
Funding environment tightens
│
▼
Profitability becomes priority
│
▼
Weak businesses face consolidation
DealShare’s proposed sale fits into this broader consolidation cycle.
The Startup Funding Environment Has Changed
During the 2021-22 funding boom, Indian startups could raise large amounts of capital at aggressive valuations.
Companies were often valued primarily on their growth potential and total addressable market.
That environment changed significantly after global interest rates increased and investors began demanding clearer paths to profitability.
DealShare’s potential valuation reset illustrates what happens when a company’s growth expectations no longer justify its previous multiple.
Startup Valuation Cycle
| Period | Investor Priority |
|---|---|
| 2020-21 | Growth and market expansion |
| 2021-22 | Scale + aggressive valuation |
| 2023 | Cost cutting |
| 2024 | Profitability |
| 2025-26 | Sustainable growth + cash efficiency |
DealShare’s current situation is therefore part of a wider repricing of private technology companies.
The Potential Deal Is More Financial Than Strategic
Industry reports suggest the proposed transaction may be primarily a financial transaction rather than a traditional operating-business acquisition.
DealShare’s operations have contracted so substantially that the value being considered appears closely tied to the company’s cash balance rather than its historical e-commerce scale.
That distinction matters.
Truemeds would not necessarily be paying for the same high-growth business that investors valued at $1.7 billion.
What Truemeds May Actually Be Buying
DealShare at peak
│
├── Brand
├── Customers
├── Growth
├── Network
└── Capital
Current DealShare
│
├── Cash
├── Remaining infrastructure
├── Distribution capabilities
└── Smaller operating business
The proposed valuation reflects that change in economic reality.
DealShare Could Have Faced A Shutdown
Earlier reports said DealShare had been considering multiple options, including a potential sale to Truemeds or Captain Fresh.
If no transaction materialized, sources indicated the company could eventually wind down operations.
The Truemeds discussions therefore potentially offer DealShare investors an alternative to a complete shutdown.
DealShare’s Reported Strategic Options
| Option | Potential Outcome |
|---|---|
| Truemeds acquisition | Share swap |
| Captain Fresh transaction | Alternative acquisition route |
| Standalone turnaround | Requires new growth strategy |
| Shutdown | Assets/cash distributed or used to settle obligations |
The Truemeds transaction is reportedly the more advanced of the acquisition discussions, but final terms have not been completed.
DealShare’s Management Has Also Changed
The company has experienced significant management turnover.
Reports indicate that DealShare’s CEO Kamaldeep Singh left several months ago, while CFO Ashish Shah also exited.
All four co-founders — Vineet Rao, Shankar Bora, Sourjyendu Medda and Rajat Shikhar — have also left the company, according to industry reporting.
Management Changes
| Position / Group | Reported Status |
|---|---|
| Vineet Rao | Left |
| Shankar Bora | Left |
| Sourjyendu Medda | Left |
| Rajat Shikhar | Left |
| Kamaldeep Singh | Left |
| Ashish Shah | Left |
The leadership changes underscore how far the company has moved from its expansion phase.
The Proposed Deal Is Not Yet Final
Despite the advanced stage of negotiations, the acquisition has not been formally completed.
Final terms, valuation, shareholding percentages and transaction structure can still change.
That is particularly important because the reported DealShare valuation is based on negotiations rather than a completed transaction.
Deal Status
| Item | Current Status |
|---|---|
| Acquisition target | Truemeds |
| Negotiations | Advanced |
| Structure | Share swap |
| DealShare valuation | Slightly above $90M cash balance |
| Truemeds valuation | ~$600M |
| Final agreement | Not announced |
| Closing | Not confirmed |
Investors should therefore treat the reported figures as proposed transaction terms rather than finalized values.
What The Deal Means For India’s Startup Ecosystem
The possible acquisition provides another example of India’s startup ecosystem moving from rapid expansion toward consolidation.
A company that once commanded a $1.7 billion valuation could potentially change hands for a price only modestly above its remaining cash.
That does not mean every startup will follow the same path, but it highlights the risks associated with building businesses around growth assumptions that eventually fail to materialize.
The Bigger Picture
DealShare’s potential sale to Truemeds represents a dramatic reversal for one of India’s once-prominent e-commerce startups. The company was valued at approximately $1.7 billion in 2022 after raising substantial venture capital, but its revenue subsequently contracted sharply, falling from ₹1,963 crore in FY23 to ₹432 crore in FY25. The proposed transaction would value DealShare at only slightly above its roughly $90 million cash balance, implying a valuation decline of more than 94% from its peak.
The proposed share-swap structure also illustrates the changing priorities of India’s startup ecosystem. Truemeds would issue shares at a reported valuation of around $600 million, while gaining access to DealShare’s cash and potentially its non-metro distribution infrastructure. For DealShare’s investors, the transaction could provide an opportunity to retain exposure to a growing company rather than see the e-commerce startup wind down.
Looking Ahead
The immediate question is whether Truemeds and DealShare can finalize the reported transaction. The proposed structure remains under discussion, and the final valuation and share-swap terms could change. If completed, the deal would give Truemeds additional capital and potentially expand its distribution capabilities outside major cities, while DealShare’s investors would receive equity in a business that is currently showing stronger revenue growth.
For India’s startup market, the deal could become another prominent example of the post-boom valuation reset. DealShare’s journey from a $1.7 billion unicorn to a potential transaction valued close to its cash balance highlights the importance of sustainable revenue growth, capital efficiency and profitability. It also shows that when growth disappears, a startup’s remaining cash and infrastructure can become more valuable than the high-growth business investors once financed.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
